Highlights
– In a real-world Campus ALL analysis of adults with Philadelphia chromosome–negative ALL treated with the pediatric-inspired GIMEMA LAL1913 protocol, pre-transplant measurable residual disease (MRD) was the dominant predictor of post–alloHSCT success.
– Three‑year overall survival (OS) and disease-free survival (DFS) were 80% and 70% for MRD‑negative patients versus 47% and 41% for MRD‑positive patients.
